Phase 3 Krascendo 1 results suggest investigational divarasib could improve survival compared with currently approved KRAS G12C inhibitors in previously treated NSCLC.
Opinion|Videos|September 3, 2025
Empowering Pharmacists in the Management of Patients With Urothelial Cancer
Listen
0:00 / 0:00
Sherry Vogt, PharmD, BCOP; and Megan Hinkley, PharmD, MBA, BCOP, discuss how pharmacists play a crucial role in managing patients with bladder cancer through treatment selection, patient education, adverse effect monitoring, and the evolving landscape of therapies including traditional chemotherapy, immunotherapy, and antibody-drug conjugates like enfortumab vedotin plus pembrolizumab.
Advertisement
0:13 Urothelial Cancer Background
9:08 Patient Education
15:45 Chemotherapy Toxicities
21:17 Unmet Needs
29:14 Antibody-Drug Conjugates
36:55 Adverse Event Management
42:30 Other Considerations
Advertisement
Related to this article
This study found that use of fixed-dose 4F-PCC is a safe, efficient alternative to weight-based dosing and can lead to cost savings for the health system.
Tucatinib’s new HER2-positive breast cancer maintenance indication extends disease control while requiring close liver monitoring and pharmacist coordination of oral therapy with ongoing antibody treatment.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
This quiz was created in collaboration with PTCE™.
Pharmacy professionals can leverage LinkedIn to build a professional brand, expand meaningful connections, share expertise, and create opportunities for career growth.
An Italian pharmacy student offers an inside look at pharmacy education in Italy, from admission and coursework to oral exams and professional training.
The PD-1 inhibitor is the first immunotherapy approved for stage II and III MSI-H/dMMR locally advanced rectal cancer and may allow eligible patients to avoid chemotherapy, radiation, and surgery.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Peptide Compounding Is Evolving: What Pharmacists Need to Know Now
2
VAX-31 Meets All Primary End Points vs PCV20 and PCV21 in Pivotal Phase 3 OPUS-1 Trial
3
Dostarlimab Receives FDA Accelerated Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
4
Fall 2026 Quiz: Test Your Pharmacy Knowledge!
5